KNOXVILLE, Tenn., Sept. 28 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (BULLETIN BOARD: PVCT) (UIR: FRK2541) announced today it has received a notice of allowance for what is anticipated to be the Company’s thirteenth U.S. patent and the fourth patent for a therapeutic medical device.
The invention, which enhances multiphoton methods for therapeutic treatment, greatly expands the scope of the Company’s device technologies for treatment of certain cancers and other pigmented lesions, such as melanoma, as well as for precision surgical applications.
“These technologies are fundamental to a range of new laser-based medical devices that should dramatically enhance the precision and effectiveness of treatments for important skin, eye and neurological disorders, and are now the subject of intensive research and development in laboratories around the world,” said Eric Wachter, Ph.D., Provectus executive vice president and co-inventor.
“Together with our earlier therapeutic device patents, such as U.S. patents 5,829,448, 5,998,597 and 6,042,603, we continue to assemble an attractive portfolio of technologies that are available for licensure to the medical device industry.”
Provectus’ laser technology harnesses the energy of ultrashort laser pulses in a precise manner that minimizes damage to tissue surrounding the targeted surgical area. In addition, Provectus’ technologies enable the selective destruction of cancerous areas and non-cancerous lesions based on the tissue’s inherent light absorption. In certain cases, this may also elicit an anti-tumor immune response that can control or eliminate metastases.
A notice of allowance is an interim designation from the Patent and Trademark Office indicating that one or more of the patent’s claims have been approved.
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc. (BULLETIN BOARD: PVCT) is a pioneering pharmaceutical company actively engaged in the design, development and marketing of a diverse portfolio of leading pharmaceutical technologies for the treatment of liver, breast and prostate cancer. In addition, Provectus has developed treatments for skin diseases and psoriasis, as well as developed a variety of other over-the-counter skin care products. Provectus’ experienced management team, comprised of several leading scientists, developed and own 12 U.S. patents, and currently are seeking approval for 18 patent applications.
For more information on Provectus, please visit the Company’s web site at http://www.pvct.com/.
Forward-Looking Statements
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward-looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.
FOR MORE INFORMATION, PLEASE CONTACT Provectus Pharmaceuticals: Craig Dees, Ph.D., CEO 865-769-4011 -or- Media Relations: Emily Carlton or George Pappas, HKA, Inc. 714-426-0444 (PST) or Emily@hkamarcom.com
Provectus Pharmaceuticals, Inc.
CONTACT: Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals,+1-865-769-4011; or Media, Emily Carlton, Emily@hkamarcom.com, or GeorgePappas, both of HKA, Inc., +1-714-426-0444, for Provectus Pharmaceuticals,Inc.
Web site: http://www.pvct.com/